NKGen Biotech Completes $16.9M Acquisition of NKMax, Gains Control of NK Cell Manufacturing
核心洞察
NKGen Biotech acquired a 65% equity stake in Korean biotech company NKMax for $16.9 million, gaining full control of global manufacturing infrastructure and intellectual property assets.
The acquisition transforms NKGen into a vertically integrated NK cell therapy company with enhanced capabilities to advance its lead Alzheimer's treatment, troculeucel.
Troculeucel has received FDA fast track designation and demonstrates cessation of disease progression or cognitive improvements in over 90% of Alzheimer's patients treated to date.
NKGen Biotech, Inc. has successfully completed its acquisition of a majority equity stake in NKMax Co., Ltd., a Korean biotechnology company, for approximately $16.9 million. The transaction marks a transformative milestone for the clinical-stage biotechnology company, granting full control over key global manufacturing infrastructure, intellectual property, and exclusive commercialization rights for its natural killer (NK) cell therapeutics platform.
The acquisition emerged from NKMax's bankruptcy proceedings in 2024, following the suspension of trading of NKMax shares on the KOSDAQ Korean Stock Exchange. Originally founded as a subsidiary of NKMax in 2017, NKGen had previously benefited from its parent company's financial backing to develop its innovative NK cell therapy platform. However, financial challenges arose when NKMax provided only $10 million of a $25 million backstop commitment initially promised to fund clinical development of NKGen's flagship Alzheimer's treatment.
Strategic Partnership and Funding
The entirety of the funding for the NKMax acquisition was provided by AlpineBrook Capital GP 1 Limited (搜索) and NKGen CEO Dr. Paul Y. Song, with terms to be finalized and disclosed in due course. AlpineBrook provided the majority of the $17 million funding to NKGen for the purchase of NKMax shares. The recapitalized, debt-free NKMax operations are now expected to be funded through 2026.
"This is more than an acquisition, it's a turning point in our company's history," said Paul Y. Song, M.D., Chairman and CEO of NKGen. "The past couple of years have been incredibly challenging, but we had an unwavering belief in the science behind our therapy and its true potential to change lives."
Troculeucel Development Progress
NKGen's lead therapeutic candidate, troculeucel, has already been granted fast track designation by the U.S. Food and Drug Administration. According to Dr. Song, the company is "consistently demonstrating cessation of disease progression and/or demonstrable cognitive improvements in over 90% of all Alzheimer's patients treated to date."
The company is currently awaiting completion of enrollment and generation of clinical and biomarker data from its double-blind randomized Phase 2 trial for moderate stage Alzheimer's disease. Troculeucel is a novel cell-based, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate being developed for the treatment of neurodegenerative disorders and a broad range of cancers.
Global Expansion Opportunities
With full ownership of NKMax's manufacturing infrastructure and intellectual property, NKGen expects to be positioned for global commercial success and further strategic partnerships. Dr. Song noted that the acquisition "will allow us to rapidly expand and forge partnerships throughout Asia and the Middle East."
The company believes that removing the uncertainty of the parent company overhang has begun to generate renewed interest from U.S. and international investors, allowing NKGen to enter a new era of opportunity and long-term growth.
Regulatory Recognition
Troculeucel represents the International Nonproprietary Name (INN) for SNK01 assigned by the World Health Organization (WHO). The WHO INN approval establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market.
The acquisition positions NKGen as an independent and vertically integrated leader in NK cell therapeutics, with the company anticipating significant investor interest as it focuses on long-term value creation for shareholders and patients worldwide.